Radiopharmaceuticals: A New Vista for Diagnosis and Treatment of Thyroid Cancer

Curr Radiopharm. 2024 Jan 11. doi: 10.2174/0118744710277275231112081003. Online ahead of print.ABSTRACTRadiopharmaceuticals are in the diagnosis and treatment of cancerous and noncancerous diseases, and a hope for optimistic effort in the field of nuclear medicine. They play a crucial role in clinical nuclear medicine by providing a tool to comprehend human disease and create efficient treatments. A detailed analysis is provided regarding the crux of molecular imaging including PET and SPECT overview for the detection of cancers. For a specified understanding of radiation therapy, topics include ranging from the selection of radionuclide to its development and manufacture, and dosage requirements to establishing the importance of I- 131 Radiotherapy in thyroid cancer. In this review, we also discussed the current state of the art of nuclear medicine in thyroid cancer, including the role of radioiodine (RAI) therapeutic scans in the diagnosis of differentiated thyroid cancer. In addition, we established a brief outlook into the current status of the research in thyroid cancer and discussed the future directions in this field.PMID:38213166 | DOI:10.2174/0118744710277275231112081003
Source: Current Radiopharmaceuticals - Category: Radiology Authors: Source Type: research